Published date: Nov 21 2023

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 21, Issue No. 10

Pages: 777–788

DOI: 10.18502/ijrm.v21i10.14533

Seyed Sobhan BahreinyStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Akram Ahangarpourakramahangarpour@gmail.comMedical Basic Sciences Research Institute, Physiology Research Center, Department of Physiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Ali Asghar HemmatiMarine Pharmaceutical Research Center, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Razieh KazemzadehStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Mohammad-Navid BastaniStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Mohammad Reza DabbaghDepartment of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.

Mojtaba AghaeiStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in females. Nesfatin-1 is a neuropeptide synthesized in the hypothalamus and other peripheral organs, and there are conflicting opinions about its correlation with PCOS.

Objective: This study aims to investigate the correlation between nesfatin-1 and PCOS and evaluates the effectiveness of nesfatin-1 as a biomarker for the detection of PCOS in women.

Materials and Methods: A systematic review and meta-analysis were conducted to identify pertinent articles from databases such as PubMed, Web of Science, Cochrane, EMBASE, Scopus, and Google Scholar. The standardized mean difference (SMD) and 95% confidence interval (CI) were calculated using a random effects model to compare group outcomes. Additionally, meta-regression and subgroup analysis were performed to elucidate sources of heterogeneity.

Results: The meta-analysis involved 12 studies with 1222 participants, and the findings revealed a significant relationship between PCOS and nesfatin-1 levels. The pooled (SMD = 0.54; 95% CI: 0.00-1.07; p = 0.04) indicated a significant difference between the evaluated groups. Moreover, a subgroup analysis showed that there was a substantial difference in nesfatin-1 levels among women with PCOS and higher homeostatic model assessment for insulin resistance ratio (SMD = 1.46; 95% CI: 0.92-2.00; p < 0.001).

Conclusion: Our meta-analysis indicates an association between high nesfatin-1 levels and PCOS. This suggests a potential role of nesfatin-1 in the development of PCOS and proposes it as a potential diagnostic biomarker for the disease. However, further research is necessary to validate these findings.

Key words: Polycystic ovary syndrome, Insulin resistance, Body mass index, Meta-analysis.

[1] McGowan MP. Polycystic ovary syndrome: A common endocrine disorder and risk factor for vascular disease. Curr Treat Options Cardiovasc Med 2011; 13: 289–301.

[2] Regidor P-A, Mueller A, Sailer M, Gonzalez Santos F, Rizo JM, Egea FM. Chronic inflammation in PCOS: The potential benefits of specialized pro-resolving lipid mediators (SPMs) in the improvement of the resolutive response. Int J Mol Sci 2020; 22: 384.

[3] Wilkes S, Murdoch A. Obesity and female fertility: A primary care perspective. J Fam Plann Reprod Health Care 2009; 35: 181–185.

[4] Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: A practical guide. Drugs 2006; 66: 903–912.

[5] Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113– 116.

[6] Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141–154.

[7] Walters KA, Gilchrist RB, Ledger WL, Teede HJ, Handelsman DJ, Campbell RE. New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends Endocrinol Metab 2018; 29: 841–852.

[8] Sulaiman NS, Rovina K, Joseph VM. Classification, extraction and current analytical approaches for detection of pesticides in various food products. J Consumer Protect Food Safety 2019; 14: 209–221.

[9] Deniz R, Gurates B, Aydin S, Celik H, Sahin I, Baykus Y, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 2012; 42: 694–699.

[10] Fernandez-Fernandez R, Martini AC, Navarro VM, Castellano JM, Dieguez C, Aguilar E, et al. Novel signals for the integration of energy balance and reproduction. Mol Cell Endocrinol 2006; 254–255: 127–132.

[11] Ademoglu EN, Gorar S, Carlioglu A, Yazici H, Dellal FD, Berberoglu Z, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest 2014; 37: 715–719.

[12] Stengel A. Nesfatin-1 - more than a food intake regulatory peptide. Peptides 2015; 72: 175–183.

[13] Prinz P, Goebel-Stengel M, Teuffel P, Rose M, Klapp BF, Stengel A. Peripheral and central localization of the nesfatin-1 receptor using autoradiography in rats. Biochem Biophys Res Commun 2016; 470: 521–527.

[14] Bani Mohammad M, Majdi Seghinsara A. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pac J Cancer Prev 2017; 18: 17–21.

[15] Alp E, Gormus U, Guducu N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol 2015; 31: 543–547.

[16] Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: Anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039–1042.

[17] Oh-I Sh, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709–712.

[18] Taskin MI, Eser B, Adali E, Kara H, Cuce C, Hismiogullari AA. NUCB2 gene polymorphism and its relationship with nesfatin-1 levels in polycystic ovary syndrome. Gynecol Endocrinol 2016; 32: 46–50.

[19] Bahreiny SS, Dabbagh MR, Ebrahimi R, Harooni E. Prevalence of autoimmune thyroiditis in women with polycystic ovary syndrome: A systematic review and meta-analysis. Iran J Obstet Gynecol Infertil 2023; 26: 94–106.

[20] Xu Y, Zhang H, Li Q, Lao K, Wang Y. The role of nesfatin-1 expression in letrozole-induced polycystic ovaries in the rat. Gynecol Endocrinol 2017; 33: 438–441.

[21] Sahin FK, Sahin SB, Ural UM, Cure MC, Senturk S, Tekin YB, et al. Nesfatin-1 and vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci 2015; 15: 57–63.

[22] Varli B, Sukur YE, Ozmen B, Erguder BI, Sonmezer M, Berker B, et al. Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome. Clin Exp Reprod Med 2021; 48: 368.

[23] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. BMJ 2009; 339: b2535.

[24] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603– 605.

[25] Hamed EA, Sayyed HG, Abbas AM, Gaber MMA, Aleem H. Nesfatin-1, dopamine, and NADPH levels in infertile women with polycystic ovary syndrome: Is there a relationship between their levels and metabolic and hormonal variables. J Reprod Infertil 2022; 23: 160–168.

[26] Faeza F, Saxena P, Jain A. Correlation of serum nesfatin- 1 level with metabolic and clinical parameters in Indian women with and without polycystic ovarian syndrome. Int J Reprod Contracep Obstet Gynecol 2023; 12: 427–431.

[27] Wang Y, Ma X, Luo J, Wang X, Han L. Expression of serum PSA, nesfatin-1, and AMH in patients with polycystic ovary syndrome. Cell Mol Biol 2022; 67: 57–63.

[28] Ali EA, AL-Jedda WA, AL-Khateeb SM, AL-Samarriae AY. The association between serum nesfatin-1 level and BMI in Iraqi patients with polycystic ovary syndrome (PCOS). Indian J Forensic Med Toxicol 2021; 15: 1490–1495.

[29] Demir Çaltekin M, Caniklioglu A, Yalcin SE, Kirmizi DA, Baser E, Yalvac ES. DLK1 and nesfatin-1 levels and the relationship with metabolic parameters in polycystic ovary syndrome: Prospective, controlled study. Turk J Obstet Gynecol 2021; 18: 124–130.

[30] Binnetoglu E, Erbag G, Gencer M, Turkon H, Asik M, Gunes F, et al. Plasma levels of nesfatin-1 in patients with polycystic ovary syndrome. Acta Medica Mediterranea 2014; 30: 201–204.

[31] Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41.

[32] Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, challenges, and guiding treatment. J Clin Endocrinol Metab 2021; 106: e1071–e1083.

[33] Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides 2014; 56: 94–110.

[34] Bahreiny SS, Harooni E, Dabbagh MR, Ebrahimi R. Circulating serum preptin levels in women with polycystic ovary syndrome: A systematic review and meta-analysis. Int J Reprod BioMed 2023; 21: 367–378.

[35] Mierzynski R, Poniedzialek-Czajkowska E, Dluski D, Patro-Malysza J, Kimber-Trojnar Z, Majsterek M, et al. Nesfatin-1 and vaspin as potential novel biomarkers for the prediction and early diagnosis of gestational diabetes mellitus. Int J Mol Sci 2019; 20: 159.

[36] Rocco ER, Mory DB, Bergamin CS, Valente F, Miranda VL, Calegare BFA, et al. Optimal cutoff points for body mass index, waist circumference and HOMA-IR to identify a cluster of cardiometabolic abnormalities in normal glucose-tolerant Brazilian children and adolescents. Arq Bras Endocrinol Metab 2011; 55: 638–645.